Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bolaget.

Datum Källa Rubrik Typ Alternativ
2018-12-18 Asarina Pharma Asarina Pharma Scientific Advisory Board gives full backing to Menstrual Migraine Phase IIA trial Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 18 Dec 2018 | Asarina Pharma

Asarina Pharma Scientific Advisory Board gives full backing to Menstrual Migraine Phase IIA trial

Migraine is more prevalent than diabetes, epilepsy and asthma combined, three times more women than men suffer from it, and 1-in-5 of those suffer from menstrual migraine. Yet currently many therapies treat the symptoms of Menstrual Migraine-but do not prevent it. Sepranolone, the new therapy from Asarina Pharma, aims to prevent Menstrual Migraine from occurring. It targets the exact brain neurosteroid-allopregnanolone-that triggers Menstrual Migraine.

Asarina Pharma’s SAB has now given its input and full backing on the proposed protocol for a Phase IIA clinical study of Sepranolone in Menstrual Migraine, to be initiated before summer 2019.

ALLOPREGNANOLONE-A NEW DISRUPTOR REVEALED. Peter Nordkild, Asarina Pharma CEO: ”Our 40 years’ plus of research has tracked down and revealed the massive emotional and behavioural disruption that Allopregnanolone, a single brain neurosteroid, can cause in millions of women’s lives. Our research has shown how our compound Sepranolone dampens the effects of Allopregnanolone. We are confident it could be a powerful, effective preventive treatment for Menstrual Migraine. This trial is an important first step.”

IMPORTANT PRECLINICAL DATA PRESENTED: The SAB was also presented with high-potential pre-clinical data indicating promising results in the treatment of other stress-induced, allopregnanolone-triggered conditions.

WORLD-CLASS SCIENTIFIC ADVISORY BOARD: Asarina Pharma’s Scientific Advisory Board consists of six scientific authorities from the fields of obstetrics, gynaecology, neurology and pharmacology-from the US, UK, Sweden and Germany. It includes:

  • Prof Anne MacGregor, a world class authority on menstrual migraine with over 200 research papers and five books to her name.
  • Asoc Prof Marco Bortolato, a recognised authority on neurodevelopmental disorders and key brain neurotransmitters including conditions impacted by Allopregnanolone such as obsessive compulsive disorder, pathological gambling and Tourette’s.
  • Prof. Dr. h.c. Günther Deuschl is one of the world’s most distinguished Professors of Neurology. He has published over 580 papers and has been president of the European Academy of Neurology.

2018-11-22 Asarina Pharma Asarina Pharma CSO presents at PMS event in Stockholm: `It's time to talk about PMDD' Pressreleaser Ladda ner | Visa Stäng
2018-11-14 Asarina Pharma Interim Report July-September 2018 Rapporter Ladda ner | Visa Stäng
2018-11-14 Asarina Pharma Delårsrapport juli-september 2018 Rapporter Ladda ner | Visa Stäng
2018-10-24 Asarina Pharma Asarina Pharma over-allotment option fully exercised as stabilization period of share offering ends Pressreleaser Ladda ner | Visa Stäng
2018-10-24 Asarina Pharma Ingen stabilisering av aktier i Asarina Pharma efter noteringen, övertilldelningsoption utnyttjas till fullo Pressreleaser Ladda ner | Visa Stäng
2018-10-23 Asarina Pharma Asarina Pharma sponsrar PMS-dagen i Stockholm. "Kvinnors hälsa påverkar oss alla, det är hög tid börja prata om PMDS". Pressreleaser Ladda ner | Visa Stäng
2018-10-23 Asarina Pharma Asarina Pharma sponsrar PMS-dagen i Stockholm. "Kvinnors hälsa påverkar oss alla, det är hög tid börja prata om PMDS". Pressreleaser Ladda ner | Visa Stäng
2018-10-23 Asarina Pharma Asarina Pharma sponsors PMS Day Stockholm `Women's health affects all of us, it's time to talk about PMDD' Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

14 Nov 2018 | Kvartalsrapport 2018-Q3
25 Feb 2019 | Bokslutskommuniké 2018
8 May 2019 | Årsstämma 2018
9 May 2019 | Årligutdelning
20 May 2019 | Kvartalsrapport 2019-Q1
20 Aug 2019 | Kvartalsrapport 2019-Q2
20 Nov 2019 | Kvartalsrapport 2019-Q3

ca.penser.se använder cookies för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder cookies. Vad är cookies?

Jag godkänner